Status:
COMPLETED
AZD9164 Single Ascending Dose Study in Healthy Male Subjects
Lead Sponsor:
AstraZeneca
Conditions:
Healthy
Eligibility:
MALE
18-45 years
Phase:
PHASE1
Brief Summary
The aims of the study are to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of AZD9164 following single ascending dose administrations to healthy male subjects.
Eligibility Criteria
Inclusion
- Provision of signed, written and dated informed consent prior to any study specific procedures
- Have a body mass index (BMI) between 19 and 30 kg/m2 and weigh at least 50 kg and no more than 100 kg
- Be non-smoker or ex-smoker who has stopped smoking (or using other nicotine products) for \>6 months prior to study start
Exclusion
- Any clinically significant disease or disorder
- Any clinically significant abnormalities at screening examinations
- Use of any prescribed or non-prescribed medication
Key Trial Info
Start Date :
February 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2009
Estimated Enrollment :
65 Patients enrolled
Trial Details
Trial ID
NCT00847249
Start Date
February 1 2009
End Date
April 1 2009
Last Update
September 23 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Lund, Sweden